Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Sep 28, 2009; 15(36): 4511-4517
Published online Sep 28, 2009. doi: 10.3748/wjg.15.4511
Published online Sep 28, 2009. doi: 10.3748/wjg.15.4511
Patients (n = 124) | n (%) |
Age (yr) | |
Range | 32.8-84.8 |
Median | 64.8 |
mean ± SD | 63.4 ± 11.0 |
Male:female | 61:63 (49:51) |
Gallbladder cancer | 33 (26.6) |
Mass forming type | 47 (37.9) |
Intraductal growth type | 44 (35.5) |
Histological type | |
Well differentiated | 8 (6.5) |
Moderately differentiated | 80 (64.5) |
Poorly differentiated | 36 (29) |
Stage1 | |
I | 9 (7.3) |
II | 20 (16.1) |
III | 31 (25) |
IV | 64 (51.6) |
Chemotherapy | 62 (50) |
Partial response | 9 (14.5) |
Stable disease | 27 (43.5) |
Progressive disease | 26 (42) |
- Citation: Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009; 15(36): 4511-4517
- URL: https://www.wjgnet.com/1007-9327/full/v15/i36/4511.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.4511